Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery

Wen Hwa Lee

PLOS Biology, 2015, vol. 13, issue 6, 1-9

Abstract: There is a scarcity of novel treatments to address many unmet medical needs. Industry and academia are finally coming to terms with the fact that the prevalent models and incentives for innovation in early stage drug discovery are failing to promote progress quickly enough. Here we will examine how an open model of precompetitive public–private research partnership is enabling efficient derisking and acceleration in the early stages of drug discovery, whilst also widening the range of communities participating in the process, such as patient and disease foundations.An open access model of precompetitive public–private research partnership can reduce the risks and increase the speed of the early stages of drug discovery, while widening participation to new communities such as patient and disease foundations.

Date: 2015
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002164 (text/html)
https://journals.plos.org/plosbiology/article/file ... 02164&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pbio00:1002164

DOI: 10.1371/journal.pbio.1002164

Access Statistics for this article

More articles in PLOS Biology from Public Library of Science
Bibliographic data for series maintained by plosbiology ().